false 0001029125 0001029125 2025-02-12 2025-02-12
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
February 12, 2025
Date of Report (Date of Earliest Event Reported)
 
 
Panbela Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
 
Delaware
  
001-39468
  
88-2805017
(State of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)
 
 
712 Vista Blvd #305
Waconia, Minnesota
  
55387
(Address of Principal Executive Offices)
  
(Zip Code)
 
(952) 479-1196
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: None.
 
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On February 12, 2025, Panbela Therapeutics, Inc. (the “Company”) reduced the annual compensation for both our Chief Executive Officer and President, Jennifer K. Simpson, and our Vice President of Finance and Chief Financial Officer, Susan Horvath. The new annual salary for Dr. Simpson is approximately$30,200. The new annual salary for Ms. Horvath is approximately $23,150.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Panbela Therapeutics, Inc.
  
Date: February 18, 2025
By:
 /s/ Susan Horvath  
   
Susan Horvath
  
   
Chief Financial Officer
  
 
 
 
v3.25.0.1
Document And Entity Information
Feb. 12, 2025
Document Information [Line Items]  
Entity, Registrant Name Panbela Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date Feb. 12, 2025
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39468
Entity, Tax Identification Number 88-2805017
Entity, Address, Address Line One 712 Vista Blvd #305
Entity, Address, City or Town Waconia
Entity, Address, State or Province MN
Entity, Address, Postal Zip Code 55387
City Area Code 952
Local Phone Number 479-1196
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001029125
Panbela Therapeutics (QB) (USOTC:PBLA)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse Panbela Therapeutics (QB)
Panbela Therapeutics (QB) (USOTC:PBLA)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse Panbela Therapeutics (QB)